OncoMatch/Clinical Trials/NCT06792695
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Is NCT06792695 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Volrustomig and FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) for metastatic colorectal cancer.
Treatment: Volrustomig · FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan) · Bevacizumab — The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MMR proficient
Known pMMR/MSS status (only pMMR/MSS mCRC allowed).
Required: MSH2 microsatellite stable
Known pMMR/MSS status (only pMMR/MSS mCRC allowed).
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immune mediated therapy
Lab requirements
Blood counts
Adequate organ and bone marrow function
Kidney function
Adequate organ and bone marrow function
Liver function
Adequate organ and bone marrow function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Scottsdale, Arizona
- Research Site · Los Angeles, California
- Research Site · Washington D.C., District of Columbia
- Research Site · Chicago, Illinois
- Research Site · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06792695 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MMR?
Yes, MMR proficient is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 microsatellite stable is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 130 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages